Regulatory FDA seeks permanent future for rare pediatric priority review vouchers Pharmaceutical TechnologyThe rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.RegulatoryRare DiseaseRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Technology The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability. RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Syneron raises $150m for macrocyclics, and other financingsNext: Jeito Capital secures over $1.2bn for new biopharma investments Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
